“When you're in a position to have gotten so much, the gift at this point is giving back.”
– Paul Stanley
Rolling dice
US pharma major Gilead licensed three Indian drug makers—Cipla, Hetero Labs, and Jubilant—to produce its purported Covid-19 cure, remdesivir
The Indian government and Indian Pharma, though, are sceptical of its efficacy and prefer not to wait for it to reach the market
Instead, they are banking on alternatives like favipiravir and tocilizumab, which are both off-patent and can be made available a lot sooner
If any of these drugs come up trumps, Indian pharma companies will be at the forefront of supplying it globally
In the first week of May, India’s health ministry convened a video call with the country’s drug makers. As cases of the novel coronavirus continued to mount, the government how they planned to bring remdesivir to India.
An antiviral drug manufactured by pharma major Gilead Sciences, the US drug regulator had recently authorised the emergency use of remdesivir for the treatment of Covid-19 patients.
Sign up to our India edition to read this story instantly
To sign up, you’ll create an account that will give you access to a new free story published once a week and archive of 214+ previously published free stories from our India edition. You’ll also receive one email every morning from us introducing the day’s story.
If you’ve already signed up, just enter your email below or login using Facebook or Google.
One free story every week. Access to 214+ older free stories from India edition
One email every morning from us, and The Nutgraf - our cracking Saturday newsletter
200 word summaries for all paid, subscriber-only stories
The Ken has invited you to sign up for The Nutgraf by The Ken.
The Ken has invited you to sign up for The Nutgraf by The Ken.
Having your name allows us to address you personally in emails and on our website. That’s all, nothing else.
The Ken has added you as a partner. Read The Ken as a couple. Sign in to get started.
The Ken has added you as a partner. Read The Ken as a couple. Sign up to get started.
Having your name allows us to address you personally in emails and on our website. That’s all, nothing else.
